

Financial news for SRDX dated on 2020-06-08: Surmodics Receives CE Mark For Its SurVeil Drug Coated Balloon

Financial news for SRDX dated on 2020-04-29: Surmodics Q2 EPS \$0.040 May Not Compare To \$(0.110) Estimate, Sales \$22.800M Beat \$20.840M Estimate

Financial news for SRDX dated on 2020-04-29: The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

Financial news for SRDX dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for SRDX dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for SRDX dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for SRDX dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for SRDX dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for SRDX dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for SRDX dated on 2020-03-11: Stocks That Hit 52-Week Lows On Wednesday

Financial news for SRDX dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for SRDX dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for SRDX dated on 2020-03-06: Stocks That Hit 52-Week Lows On Friday

Financial news for SRDX dated on 2020-03-06: The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study

Financial news for SRDX dated on 2020-03-05: Stocks That Hit 52-Week Lows On Thursday

Financial news for SRDX dated on 2020-03-04: The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

Financial news for SRDX dated on 2020-02-28: Stocks That Hit 52-Week Lows On Friday

Financial news for SRDX dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for SRDX dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for SRDX dated on 2020-02-20: Stocks That Hit 52-Week Lows On Thursday

Financial news for SRDX dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for SRDX dated on 2020-02-05: Surmodics Q1 EPS \$0.05 Beats \$(0.08) Estimate, Sales \$22.616M Beat \$22.08M Estimate

Financial news for SRDX dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for SRDX dated on 2020-02-02: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Financial news for SRDX dated on 2019-12-11: Benzinga's Top Upgrades, Downgrades For December 11, 2019

Financial news for SRDX dated on 2019-12-11: Needham Downgrades Surmodics to Hold

Financial news for SRDX dated on 2019-11-04: 58 Biggest Movers From Friday

Financial news for SRDX dated on 2019-11-01: 50 Stocks Moving In Friday's Mid-Day Session

Financial news for SRDX dated on 2019-11-01: Benzinga's Top Upgrades, Downgrades For November 1, 2019

Financial news for SRDX dated on 2019-11-01: Lake Street Downgrades Surmodics to Hold

Financial news for SRDX dated on 2019-10-31: Surmodics Sees FY20 EPS Guidance \$(0.60)-\$(0.30) Vs. \$0.51 Est., Sales \$87M-\$91M Vs. 104.8M Est.

Financial news for SRDX dated on 2019-10-31: Surmodics Q4 EPS \$0.37 Up From \$0.05 YoY, Sales \$30.8M Up From \$23.038M YoY

Financial news for SRDX dated on 2019-10-29: Surmodics Reports Sundance Sirolimus-Coated Balloon Catheter Wins FDA Breakthrough Device Status

Financial news for SRDX dated on 2019-08-28: Surmodics Completes Enrollment In Pivotal TRANSCEND Clinical Trial

Financial news for SRDX dated on 2019-08-02: 100 Biggest Movers From Yesterday

Financial news for SRDX dated on 2019-08-01: The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Financial news for SRDX dated on 2019-08-01: 28 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for SRDX dated on 2019-07-31: The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

Financial news for SRDX dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for SRDX dated on 2019-05-21: The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

Financial news for SRDX dated on 2019-05-01: SurModics Q2 EPS \$0.07 Beats \$(0.02) Estimate, Sales \$22.676M Beat \$22.03M Estimate

Financial news for SRDX dated on 2019-05-01: The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

Financial news for SRDX dated on 2019-04-23: Surmodics Reports Its Sublime Guide Sheath Received FDA 510(k) Approval

Financial news for SRDX dated on 2019-04-17: Surmodics Offers Update Related To TRANSCEND Trial

Financial news for SRDX dated on 2019-03-18: Surmodics Says it is Assessing the Impact From an FDA Communication on the Potential for Increased Mortality After Use of Paclitaxel-Coated Balloons On its TRANSCEND Clinical Trial

Financial news for SRDX dated on 2019-02-04: 60 Biggest Movers From Friday

Financial news for SRDX dated on 2019-02-01: 45 Stocks Moving In Friday's Mid-Day Session

Financial news for SRDX dated on 2019-02-01: 64 Biggest Movers From Yesterday

Financial news for SRDX dated on 2019-01-31: 48 Stocks Moving In Thursday's Mid-Day Session

Financial news for SRDX dated on 2019-01-31: The Daily Biotech Pulse: Hologic, Celgene Earnings, FDA To Rule On Alkermes Depression Drug

Financial news for SRDX dated on 2019-01-30: Surmodics Narrows FY19 Sales Guidance From \$92M-\$97M To \$94M-\$97M vs \$93.8M Estimate, Adj. EPS From \$(0.07)-\$0.23 To \$0.02-\$0.22 vs \$0.09 Est.

Financial news for SRDX dated on 2019-01-30: SurModics Q1 EPS \$0.12 Up From \$0.10 YoY, Sales \$22.241M Beat \$20.18M Estimate

Financial news for SRDX dated on 2019-01-30: The Daily Biotech Pulse: Roche Scraps Alzheimer's Disease Trials, Amgen Issues Weak Guidance

Financial news for SRDX dated on 2019-01-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for SRDX dated on 2018-11-09: SurModics Sees FY19 Adj. EPS \$(0.07)-\$0.23 vs \$0.23 Estimate, Sales \$92M-\$97M vs \$90.37M Est.

Financial news for SRDX dated on 2018-11-09: SurModics, Inc. Q4 EPS \$0.05 Beats \$(0.03) Estimate, Sales \$23.038M Beat \$21.56M Estimate

Financial news for SRDX dated on 2018-11-09: The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Financial news for SRDX dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for SRDX dated on 2018-09-05: Stocks Which Set New 52-Week High Yesterday, September 4th

Financial news for SRDX dated on 2018-09-04: Stocks Which Set New 52-Week High Friday, August 31

Financial news for SRDX dated on 2018-08-31: Stocks Which Set New 52-Week High Yesterday, August 30th

Financial news for SRDX dated on 2018-08-31: The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage

Financial news for SRDX dated on 2018-08-29: Stocks Which Set New 52-Week High Yesterday, August 28th

Financial news for SRDX dated on 2018-08-24: Stocks Which Set New 52-Week High Yesterday, August 23rd

Financial news for SRDX dated on 2018-08-24: The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict

Financial news for SRDX dated on 2018-08-23: Stocks Which Set New 52-Week High Yesterday, August 22nd

Financial news for SRDX dated on 2018-08-17: Stocks Which Set New 52-Week High Yesterday, August 16th

Financial news for SRDX dated on 2018-08-16: Stocks Which Set New 52-Week High Yesterday, August 15th

Financial news for SRDX dated on 2018-08-15: Stocks Which Set New 52-Week High Yesterday, August 14th

Financial news for SRDX dated on 2018-08-15: The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue

Financial news for SRDX dated on 2018-08-14: The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

Financial news for SRDX dated on 2018-08-10: Stocks Which Set New 52-Week High Yesterday, August 9th

Financial news for SRDX dated on 2018-08-09: Stocks Which Set New 52-Week High Yesterday, August 8th

Financial news for SRDX dated on 2018-08-09: The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

Financial news for SRDX dated on 2018-08-07: Stocks Which Set New 52-Week High Yesterday, August 6th

Financial news for SRDX dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Financial news for SRDX dated on 2018-08-07: 52 Biggest Movers From Yesterday

Financial news for SRDX dated on 2018-08-06: Surmodics shares are trading up 10.5% after the company beat Q2 sales estimates and raised 2018 sales guidance.

Financial news for SRDX dated on 2018-08-06: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for SRDX dated on 2018-08-06: Surmodics Raises FY18 Sales Outlook From \$75M-\$79M To \$79M-\$81M vs \$76.8M Est.

Financial news for SRDX dated on 2018-08-06: SurModics Q3 EPS \$0.27 May Not Compare To \$(0.24) Estimate, Sales \$22.2M Beat \$19.38M Estimate

Financial news for SRDX dated on 2018-07-27: Stocks Which Set New 52-Week High Yesterday, July 26th:

Financial news for SRDX dated on 2018-07-25: Stocks Which Set New 52-Week High Yesterday, July 24th:

Financial news for SRDX dated on 2018-07-24: Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering

Financial news for SRDX dated on 2018-07-23: Stocks Which Set New 52-Week Highs Friday

Financial news for SRDX dated on 2018-07-20: Stocks Which Set New 52-Week High Yesterday

Financial news for SRDX dated on 2018-07-20: Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2

Financial news for SRDX dated on 2018-07-05: Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index

Financial news for SRDX dated on 2018-06-15: Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug

Financial news for SRDX dated on 2018-06-12: Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate

Financial news for SRDX dated on 2018-06-01: Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO

Financial news for SRDX dated on 2018-05-31: Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time

Financial news for SRDX dated on 2018-05-30: Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immuteq Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA

Financial news for SRDX dated on 2018-05-24: Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

Financial news for SRDX dated on 2018-05-17: Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

Financial news for SRDX dated on 2018-05-16: Surmodics Reports CFO Andrew LaFrence Resigned; Timothy Arens Named As Interim Replacement

Financial news for SRDX dated on 2018-05-15: Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway

Financial news for SRDX dated on 2018-05-14: Surmodics Reports Purchase Of Thrombectomy Technology Assets From Embolitech For \$5M In Upfront Payment, Added Undetermined Amounts Related To Regulatory Milestones

Financial news for SRDX dated on 2018-05-09: Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

Financial news for SRDX dated on 2018-05-02: Surmodics Raises FY2018 EPS Guidance from \$(0.20)-0.05 to \$(0.06)-0.09 vs \$(0.11) Est; Raises FY2018 Sales Guidance from \$72.0M-75.0M to \$75.0M-79.0M vs \$73.80M Est

Financial news for SRDX dated on 2018-05-02: SurModics Q2 EPS \$0.15 Beats \$(0.08) Estimate, Sales \$19.058M Beat \$17.71M Estimate

Financial news for SRDX dated on 2018-04-23: Surmodics Reports FDA Clearance For New 0.18" Low-Profile PTA Balloon Dilation Catheter

Financial news for SRDX dated on 2018-03-06: Mid-Morning Market Update: Markets Mostly Higher; Ciena Profit Tops Expectations

Financial news for SRDX dated on 2018-02-28: Benzinga's Top Upgrades, Downgrades For February 28, 2018

Financial news for SRDX dated on 2018-02-28: Barrington Research Upgrades Surmodics

to Outperform

Financial news for SRDX dated on 2018-02-28: Needham Initiates Coverage On Surmodics with Buy Rating, Announces \$42.00 Price Target

Financial news for SRDX dated on 2018-02-28: 42 Biggest Movers From Yesterday

Financial news for SRDX dated on 2018-02-27: 35 Stocks Moving In Tuesday's Mid-Day Session

Financial news for SRDX dated on 2018-02-27: Abbott, Surmodics Announce Agreement for Next-Generation Drug-Coated Balloon; Abbott To Receive Exclusive Worldwide Commercialization Rights For SurVeil

Financial news for SRDX dated on 2018-02-08: Surmodics Sees FY18 Adj. EPS \$(0.20)-\$(0.05) vs \$(0.36) Est., Sale \$72M-\$75M vs \$73.9M Est.

Financial news for SRDX dated on 2018-02-08: Surmodics Reports Q1 Adj. EPS \$0.10 vs \$0.19 In Same Qtr. Last Year, Sales \$17M vs \$17.8M YoY

Financial news for SRDX dated on 2018-01-22: Surmodics Receives 510(K) Clearance for Telemark Coronary/Peripheral Support Microcatheter from the U.S. Food and Drug Administration

Financial news for SRDX dated on 2017-11-08: Surmodics Sees FY18 Adj. EPS \$(0.41)-\$(0.16), Sales \$72M-\$75M vs \$73.8M Est.

Financial news for SRDX dated on 2017-11-08: Surmodics Reports Q4 Adj. EPS \$0.18 May Not Compare To \$(0.01) Est., Sales \$20.1M vs \$17M Est.

Financial news for SRDX dated on 2017-10-31: Companies Holding Analyst/Investor Days Today Include Abiomed and Surmodics

Financial news for SRDX dated on 2017-08-03: Surmodics Raises FY17 Outlook: Sales \$65M-\$68M TO \$70M-\$72M vs \$67.5M Est., Adj. EPS From \$0.15-\$0.25 To \$0.29-\$0.39 vs \$0.19 Est.

Financial news for SRDX dated on 2017-08-03: Surmodics Reports Q3 Adj. EPS \$0.09, Sales \$17.8M vs \$16M Est.

Financial news for SRDX dated on 2017-07-14: Lake Street Initiates Coverage On Surmodics with Buy Rating, Announces \$40.00 Price Target

Financial news for SRDX dated on 2017-06-27: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for SRDX dated on 2017-06-27: Mid-Morning Market Update: Markets Open Lower; EU Slaps Google Parent Alphabet With \$2.7 Billion Fine

Financial news for SRDX dated on 2017-06-27: Benzinga's Top Upgrades, Downgrades For June 27, 2017

Financial news for SRDX dated on 2017-06-27: Aegis Capital Initiates Coverage On Surmodics with Buy Rating, Announces \$43.50 Price Target

Financial news for SRDX dated on 2017-04-27: Surmodics Narrows FY17 Sales Outlook from \$64M-\$68M to \$65M-\$68M, Cuts Adj. EPS Guidance from \$0.18-\$0.33 to \$0.15-\$0.25

Financial news for SRDX dated on 2017-04-27: Surmodics Reports Q2 Adj. EPS \$0.05 vs \$0.07 Est., Sales \$17.5M vs \$16.2M Est.

Financial news for SRDX dated on 2017-03-08: Why Is Surmodics (SRDX) Down 2.7% Since the Last Earnings Report?

Financial news for SRDX dated on 2017-02-02: UPDATE: Surmodics Raises FY17 Outlook: Adj. EPS from \$0.15-\$0.35 to \$0.18-\$0.33 vs \$0.24 Est., GAAP Sales from \$63M-\$67M to \$64M-\$68M vs \$65.3M Est.

Financial news for SRDX dated on 2017-02-02: Surmodics Raises Outlook

Financial news for SRDX dated on 2017-02-02: Surmodics Reports Q1 Adj. EPS \$0.19 vs \$0.09 Est., Sales \$17.8M vs \$15.8M Est.

Financial news for SRDX dated on 2016-11-21: Barrington Research Downgrades Surmodics to Market Perform

Financial news for SRDX dated on 2016-11-17: Canaccord Genuity Medical Technology And Diagnostics Forum Today

Financial news for SRDX dated on 2016-11-16: Surmodics Sees FY17 Adj. EPS

\$0.15-\$0.35, GAAP Sales \$63M-\$67M vs \$69.3M Est.

Financial news for SRDX dated on 2016-11-16: Surmodics Reports Q4 Adj. EPS \$0.26 vs \$0.34 in Same Qtr. Last Year, Sales \$18.2M vs \$16M Est.

Financial news for SRDX dated on 2016-11-16: Earnings Scheduled For November 16, 2016

Financial news for SRDX dated on 2016-08-01: Surmodics IVD Launches Breakthrough StabilBlock Immunoassay Stabilizer

Financial news for SRDX dated on 2016-07-28: Surmodics Reports Q3 EPS \$0.37 Does Not Compare To Est. \$0.12, Rev. \$20M vs. Est. \$16.3M

Financial news for SRDX dated on 2016-07-12: Upcoming Non-Deal Road Shows For Syntel, Franklin Covey And Others

Financial news for SRDX dated on 2016-05-02: Surmodics Reports Q2 Cont. Ops EPS \$0.06, Non GAAP EPS \$0.20, Sales \$16.7M Vs est \$15.13M

Financial news for SRDX dated on 2016-04-06: SurModics Reports First Patient Enrolled in IDE Study of SurVeil Drug-Coated Balloon

Financial news for SRDX dated on 2016-04-06: SurModics Reports Initial Patient Enrolled in IDE Study of SurVeil Drug-Coated Balloon

Financial news for SRDX dated on 2016-01-28: SurModics Reports Q1 EPS \$0.38 vs. Est. \$0.17, Rev. \$16.5M vs. Est. \$14.58M

Financial news for SRDX dated on 2016-01-11: SurModics Sees FY2016 Sales \$62.0M-66.0M vs \$59.55M Est

Financial news for SRDX dated on 2016-01-11: Surmodics Announces Acquisition of Normedix for \$14M

Financial news for SRDX dated on 2016-01-08: UPDATE: SurModics Sees FY16 GAAP Sales \$60M-\$64M vs \$63M Est.

Financial news for SRDX dated on 2016-01-08: SurModics Sees FY16 Adj. EPS \$0.66-\$0.75 vs \$0.73 Est.

Financial news for SRDX dated on 2015-11-10: SurModics Raises Buyback Plan to \$30M; Sees FY16 GAAP EPS \$0.70-\$0.80, Sales \$56M-\$60M vs \$59.8M Est.

Financial news for SRDX dated on 2015-11-10: SurModics Reports Q4 EPS \$0.22 Vs Est \$0.19, Sales \$17.4M Vs Est \$15.30M

Financial news for SRDX dated on 2015-10-05: SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil(tm) Drug-Coated Balloon

Financial news for SRDX dated on 2015-09-16: Top 4 Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for SRDX dated on 2015-08-05: SurModic Reports Q3 EPS \$0.30 Vs Est \$0.21, Sales \$15.9M vs Est \$14.87M; Raises FY EPS To \$0.95-\$1.00 Vs Est \$0.89 & Revs Up To \$58M-\$60M Vs Est \$58.69M

Financial news for SRDX dated on 2015-06-23: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Operating Margin

Financial news for SRDX dated on 2015-06-08: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS

Financial news for SRDX dated on 2015-05-05: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROA

Financial news for SRDX dated on 2015-04-30: SurModic Reports Q2 EPS \$0.23 Vs Est \$0.23, Sales \$14.4M Vs Est \$13.97M

Financial news for SRDX dated on 2015-02-12: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest EPS

Financial news for SRDX dated on 2015-01-29: SurModics Reports Q1 EPS \$0.27 Vs Est \$0.21, Revs \$14.2M Vs Est \$14.29M

Financial news for SRDX dated on 2015-01-22: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROI

Financial news for SRDX dated on 2014-12-31: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for SRDX dated on 2014-12-18: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROI

Financial news for SRDX dated on 2014-12-15: Barrington Research Assumes SurModics, Inc. at Outperform, Maintains \$28.00 PT

Financial news for SRDX dated on 2014-11-12: SurModics Announces \$20M Accelerated Share Repurchase Program

Financial news for SRDX dated on 2014-11-06: SurModics, Inc. Sees FY2015 ADJ. EPS \$0.85-0.95

Financial news for SRDX dated on 2014-11-06: SurModics, Inc. Reports Q4 EPS of \$0.26 vs \$0.25 Est; Revenue of \$15.30M vs \$14.92M Est

Financial news for SRDX dated on 2014-10-08: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS

Financial news for SRDX dated on 2014-08-01: Morning Market Movers

Financial news for SRDX dated on 2014-07-31: SurModics, Inc. Sees FY2014 EPS \$0.90-0.97; Sees Sales \$56.0M-58.50M

Financial news for SRDX dated on 2014-07-31: SurModics, Inc. Reports Q2 EPS of \$0.26 vs \$0.23 Est; Revenue of \$14.60M vs \$14.84M Est

Financial news for SRDX dated on 2014-07-31: S-3 Filing from Surmodics Shows Registration for \$175M Mixed Securities Shelf Offering

Financial news for SRDX dated on 2014-07-28: Stocks Hitting 52-Week Lows

Financial news for SRDX dated on 2014-07-14: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROI

Financial news for SRDX dated on 2014-05-01: SurModics, Inc. Lowers FY2014 Sales Guidance from \$58.0M-62.0M to \$56.0M-58.50M vs \$59.30M Est

Financial news for SRDX dated on 2014-05-01: SurModics, Inc. Reports Q2 EPS of \$0.22 vs \$0.20 Est; Reaffirms Outlook

Financial news for SRDX dated on 2014-04-23: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest EPS

Financial news for SRDX dated on 2014-04-11: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROA

Financial news for SRDX dated on 2014-04-04: Benzinga's Top Initiations

Financial news for SRDX dated on 2014-04-04: Benchmark Initiates Coverage on SurModics, Inc. at Buy, Announces \$30.00 PT

Financial news for SRDX dated on 2014-03-20: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates

Financial news for SRDX dated on 2014-02-25: Laidlaw & Co. Initiates Coverage on SurModics, Inc. at Buy, Announces \$30.00 PT

Financial news for SRDX dated on 2014-02-13: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for SRDX dated on 2014-01-30: SurModics, Inc. Reports Q4 EPS of \$0.21, Inline; Revenue of \$13.90M vs \$14.15M Est

Financial news for SRDX dated on 2014-01-15: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS

Financial news for SRDX dated on 2013-12-30: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROA

Financial news for SRDX dated on 2013-12-11: SurModics Affirms FY14 Outlook

Financial news for SRDX dated on 2013-11-06: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Operating Margin

Financial news for SRDX dated on 2013-11-05: SurModics, Inc. Sees FY2014 EPS \$0.80-0.92 vs \$0.93 Est; Sees Sales \$58.0M-62.0M vs \$62.52M Est

Financial news for SRDX dated on 2013-11-05: SurModics, Inc. Reports Q4 EPS of \$0.26

vs \$0.22 Est; Revenue of \$14.30M vs \$14.82M Est

Financial news for SRDX dated on 2013-11-01: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for SRDX dated on 2013-10-22: How to Profit from the Expected Obamacare Rally

Financial news for SRDX dated on 2013-10-01: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for SRDX dated on 2013-09-25: Shares of Bioscrips Spike into Positive Territory Following Positive Mention on CNBC, Shares of SurModics Also Moving

Financial news for SRDX dated on 2013-09-03: SurModics Reports Organizational Changes, Cutting 7 Jobs, 6% of Staff, Expecting Q4 Charge of \$0.02/Share

Financial news for SRDX dated on 2013-08-19: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for SRDX dated on 2013-08-05: UPDATE: Barrington Research Upgrades SurModics on Stable Cash Flow

Financial news for SRDX dated on 2013-08-05: Barrington Research Upgrades SurModics, Inc. to Outperform, Announces \$27.00 PT

Financial news for SRDX dated on 2013-08-02: Form 8-K from Surmodics, SRI Shows Settlement to Resolve Litigation

Financial news for SRDX dated on 2013-08-01: Feltl & Co. Upgrades SurModics, Inc. to Strong Buy

Financial news for SRDX dated on 2013-07-31: SurModics, Inc. Reports Q2 EPS of \$0.21, Inline; Revenue of \$14.30M vs \$15.03M Est

Financial news for SRDX dated on 2013-05-30: Afternoon Market Losers

Financial news for SRDX dated on 2013-05-07: SurModics, Inc. Reports Q2 EPS of \$0.28 vs \$0.21 Est; Revenue of \$13.70M vs \$13.92M Est

Financial news for SRDX dated on 2013-04-30: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for SRDX dated on 2013-04-18: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Operating Margin

Financial news for SRDX dated on 2013-02-21: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates For The Next Quarter

Financial news for SRDX dated on 2013-01-30: SurModics Authorizes \$10M Buyback Plan

Financial news for SRDX dated on 2013-01-30: SurModics, Inc. Sees FY2013 EPS \$0.86-0.99 vs \$0.82 Est

Financial news for SRDX dated on 2013-01-30: SurModics, Inc. Reports Q1 EPS of \$0.29 vs \$0.18 Est; Revenue of \$13.85M vs \$13.63M Est

Financial news for SRDX dated on 2013-01-25: Barrington Research Downgrades SurModics, Inc. to Market Perform

Financial news for SRDX dated on 2012-12-21: SurModics Names Andy Lafrence CFO

Financial news for SRDX dated on 2012-11-12: Barrington Research Maintains SurModics at Outperform, Raises PT from \$20 to \$22

Financial news for SRDX dated on 2012-11-07: Feltl and Company Maintains SurModics at Buy, Raises PT from \$20 to \$21.50

Financial news for SRDX dated on 2012-11-06: SurModics Guides FY13 Sales \$55-58M vs \$56.64M Est, EPS \$0.75-0.87 vs \$0.81 Est

Financial news for SRDX dated on 2012-11-06: SurModics Reports Q4 EPS \$0.19 vs \$0.13 Est; Revenues \$13.8M vs \$12.39M Est

Financial news for SRDX dated on 2012-10-03: Stocks Hitting 52-Week Highs

Financial news for SRDX dated on 2012-09-11: Surmodics Accepted 2.89M Shares at \$19 a Piece

Financial news for SRDX dated on 2012-09-06: Surmodics Announces Buyback of 2.89M Shares At \$19 Each

Financial news for SRDX dated on 2012-08-27: SurModics Announces Resignation of Jeffrey Smith from the Board of Directors

Financial news for SRDX dated on 2012-08-06: Benzinga'a M&A Chatter for Monday August 6, 2012

Financial news for SRDX dated on 2012-08-06: UPDATE: Barrington Research Reiterates Outperform Rating, Raises PT on SurModics

Financial news for SRDX dated on 2012-08-06: SurModics Announces Commencement of Tender Offer to Purchase up to \$55 Million of Its Common Stock

Financial news for SRDX dated on 2012-08-06: SurModics Commences Tender Offer to Acquire \$65M of Its Common Stock

Financial news for SRDX dated on 2012-08-06: Barrington Research Maintains SurModics at Outperform, Raises PT from \$18 to \$20

Financial news for SRDX dated on 2012-08-02: Feltl and Company Upgrades SurModics from Hold to Buy, Raises PT from \$15 to \$20

Financial news for SRDX dated on 2012-08-02: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Cash

Financial news for SRDX dated on 2012-08-01: SurModics Reports Q3 EPS \$0.18 vs \$0.13 Est; Revenues \$14M vs \$12.39M Est

Financial news for SRDX dated on 2012-08-01: SurModics Halted Pending News

Financial news for SRDX dated on 2012-07-13: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Cash

Financial news for SRDX dated on 2012-05-08: SurModics Reports Q2 EPS \$0.14 vs \$0.12 Est; Revenues \$12.2M vs \$12.30M Est

Financial news for SRDX dated on 2012-03-30: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for SRDX dated on 2012-02-13: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for SRDX dated on 2012-02-10: Surmodics Files to Delay 10-Q Filing

Financial news for SRDX dated on 2012-02-06: Barrington Research Maintains SurModics Outperform

Financial news for SRDX dated on 2012-02-03: From Earlier: SurModics Sees Q1 EPS of \$0.12 vs \$0.11 Est

Financial news for SRDX dated on 2011-11-07: Barrington Research Reiterates Outperform on SurModics; PT \$18

Financial news for SRDX dated on 2011-11-02: Feltl & Company Upgrades SurModics to Buy, \$13 PT

Financial news for SRDX dated on 2011-11-02: SurModics Announces Agreement to Sell Pharmaceutical Assets for \$30M

Financial news for SRDX dated on 2011-08-23: Surmodics Cutting 9% of Workforce, Including CFO Ankeny

Financial news for SRDX dated on 2011-08-05: NASDAQ Top Percentage Gainers: Web.com, SurModics, Air Transport Group, Insight Enterprises

Financial news for SRDX dated on 2011-06-15: SurModics Comments on Johnson & Johnson Announcement; Reaffirms 2011 Guidance

Financial news for SRDX dated on 2011-04-28: Gainers on Thursday to Watch on Friday

Financial news for SRDX dated on 2011-01-28: SRDX Beats on EPS, Sales Slip - Analyst Blog

Financial news for SRDX dated on 2011-01-28: SRDX Beats on EPS, Sales Slip - Analyst Blog

Financial news for SRDX dated on 2011-01-18: SurModics Upped to Neutral - Analyst

Blog

Financial news for SRDX dated on 2011-01-18: SurModics Upped to Neutral - Analyst Blog

Financial news for SRDX dated on 2010-12-15: SurModics May Drop Pharma Unit - Analyst Blog

Financial news for SRDX dated on 2010-12-15: SurModics May Drop Pharma Unit - Analyst Blog

Financial news for SRDX dated on 2010-12-15: SurModics May Sell Business Unit, Shares Surge 14.4% (SRDX)

Financial news for SRDX dated on 2010-12-15: Top Performing Industries For December 15 (CTRP, RF, SRDX, NWL)

Financial news for SRDX dated on 2010-12-15: SurModics Trading Substantially Higher Today

Financial news for SRDX dated on 2010-12-14: SurModics Names Gary R. Maharaj President, CEO

Financial news for SRDX dated on 2010-12-14: SurModics to Explore Strategic Alternatives for its Pharmaceuticals Business

Financial news for SRDX dated on 2010-12-10: Options Brief: SurModics, Inc. (SRDX)

Financial news for SRDX dated on 2010-12-02: SurModics, Inc. (SRDX) - Bear of the Day

Financial news for SRDX dated on 2010-12-01: SurModics, Inc. (SRDX) - Bear of the Day

Financial news for SRDX dated on 2010-12-01: SurModics Cut to Underperform - Analyst Blog

Financial news for SRDX dated on 2010-12-01: SurModics Cut to Underperform - Analyst Blog

Financial news for SRDX dated on 2010-11-17: Ramius Reports 12% Ownership In SurModics

Financial news for SRDX dated on 2010-11-12: SurModics Disappoints in Q4 - Analyst Blog

Financial news for SRDX dated on 2010-11-11: SurModics Getting Killed, Down 27% (SRDX)

Financial news for SRDX dated on 2010-11-11: Some Ugly Issues This Morning (ANW, RST, SRDX)

Financial news for SRDX dated on 2010-11-10: SurModics Falls 22% After Hours (SRDX)

Financial news for SRDX dated on 2010-11-10: SurModics Reports Fourth Quarter and Fiscal Year 2010 Results: Loss Per Share of \$0.05

Financial news for SRDX dated on 2010-09-21: SurModics Announces New Board Director

Financial news for SRDX dated on 2010-09-13: SurModics Stays Neutral - Analyst Blog

Financial news for SRDX dated on 2010-08-04: SurModics Falls Short - Analyst Blog

Financial news for SRDX dated on 2010-08-03: Benzinga's Top Upgrades (CEPH, ENR, SRDX, DY)

Financial news for SRDX dated on 2010-08-03: Barrington Upgrades SRDX To Market Perform

Financial news for SRDX dated on 2009-10-06: Today's Morning Top Gainers (FONR, AVCT, ICTG, KGN, SRDX)